Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M

Natera, Inc.

2025-Q2 EPS reported -$1.24 revenue$1,048,431,000

Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).
Oncology tests grew 50.6% to 188,800; total tests processed 853,100 (+12.2%).
Achieved positive cash flow of ~$24.3M in Q2; cash and investments $1,016M.
Net loss per diluted share ($0.74) vs ($0.30) in Q2 2024, impacted by $19.8M legal accruals.
Raising 2025 revenue guidance to $2.02B-$2.10B from $1.94B-$2.02B; OpEx outlook unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.